1
|
Divaris K, Haworth S, Shaffer J, Anttonen V, Beck J, Furuichi Y, Holtfreter B, Jönsson D, Kocher T, Levy S, Magnusson P, McNeil D, Michaëlsson K, North K, Palotie U, Papapanou P, Pussinen P, Porteous D, Reis K, Salminen A, Schaefer A, Sudo T, Sun Y, Suominen A, Tamahara T, Weinberg S, Lundberg P, Marazita M, Johansson I. Phenotype Harmonization in the GLIDE2 Oral Health Genomics Consortium. J Dent Res 2022; 101:1408-1416. [PMID: 36000800 PMCID: PMC9516613 DOI: 10.1177/00220345221109775] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Genetic risk factors play important roles in the etiology of oral, dental, and craniofacial diseases. Identifying the relevant risk loci and understanding their molecular biology could highlight new prevention and management avenues. Our current understanding of oral health genomics suggests that dental caries and periodontitis are polygenic diseases, and very large sample sizes and informative phenotypic measures are required to discover signals and adequately map associations across the human genome. In this article, we introduce the second wave of the Gene-Lifestyle Interactions and Dental Endpoints consortium (GLIDE2) and discuss relevant data analytics challenges, opportunities, and applications. In this phase, the consortium comprises a diverse, multiethnic sample of over 700,000 participants from 21 studies contributing clinical data on dental caries experience and periodontitis. We outline the methodological challenges of combining data from heterogeneous populations, as well as the data reduction problem in resolving detailed clinical examination records into tractable phenotypes, and describe a strategy that addresses this. Specifically, we propose a 3-tiered phenotyping approach aimed at leveraging both the large sample size in the consortium and the detailed clinical information available in some studies, wherein binary, severity-encompassing, and "precision," data-driven clinical traits are employed. As an illustration of the use of data-driven traits across multiple cohorts, we present an application of dental caries experience data harmonization in 8 participating studies (N = 55,143) using previously developed permanent dentition tooth surface-level dental caries pattern traits. We demonstrate that these clinical patterns are transferable across multiple cohorts, have similar relative contributions within each study, and thus are prime targets for genetic interrogation in the expanded and diverse multiethnic sample of GLIDE2. We anticipate that results from GLIDE2 will decisively advance the knowledge base of mechanisms at play in oral, dental, and craniofacial health and disease and further catalyze international collaboration and data and resource sharing in genomics research.
Collapse
Affiliation(s)
- K. Divaris
- Division of Pediatric and Public
Health, Adams School of Dentistry, University of North Carolina at Chapel Hill,
Chapel Hill, NC, USA
- Department of Epidemiology, Gillings
School of Global Public Health, University of North Carolina at Chapel Hill, Chapel
Hill, NC, USA
| | - S. Haworth
- Medical Research Council Integrative
Epidemiology United, Department of Population Health Sciences, Bristol Medical
School, University of Bristol, Bristol, UK
- Bristol Dental School, University of
Bristol, Bristol, UK
| | - J.R. Shaffer
- Department of Human Genetics, Graduate
School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
- Center for Craniofacial and Dental
Genetics, Department of Oral and Craniofacial Sciences, School of Dental Medicine,
University of Pittsburgh, Pittsburgh, PA, USA
| | - V. Anttonen
- Research Unit of Oral Health Sciences,
Faculty of Medicine, University of Oulu, Oulu, Finland
- Medical Research Center, Oulu
University Hospital and University of Oulu, Oulu, Finland
| | - J.D. Beck
- Division of Comprehensive Oral
Health–Periodontology, Adams School of Dentistry, University of North Carolina at
Chapel Hill, Chapel Hill, NC, USA
| | - Y. Furuichi
- Division of Endodontology and
Periodontology, Department of Oral Rehabilitation, Graduate School of Dentistry,
Health Sciences University of Hokkaido, Hokkaido, Japan
| | - B. Holtfreter
- Department of Restorative Dentistry,
Periodontology, Endodontology, and Preventive and Pediatric Dentistry, University
Medicine Greifswald, Greifswald, Germany
| | - D. Jönsson
- Public Dental Service of Skåne, Lund,
Sweden
- Hypertension and Cardiovascular
Disease, Department of Clinical Sciences in Malmö, Lund University, Malmö,
Sweden
- Faculty of Odontology, Malmö
University, Malmö, Sweden
| | - T. Kocher
- Department of Restorative Dentistry,
Periodontology, Endodontology, and Preventive and Pediatric Dentistry, University
Medicine Greifswald, Greifswald, Germany
| | - S.M. Levy
- Department of Preventive and
Community Dentistry, College of Dentistry, University of Iowa, Iowa City, IA,
USA
| | - P.K.E. Magnusson
- Department of Medical Epidemiology
and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - D.W. McNeil
- Center for Oral Health Research in
Appalachia, Appalachia, NY, USA
- Department of Psychology, West
Virginia University, Morgantown, WV, USA
- Department of Dental Public Health
& Professional Practice, West Virginia University, Morgantown, WV, USA
| | - K. Michaëlsson
- Department of Surgical Sciences, Unit
of Medical Epidemiology, Uppsala University, Uppsala, Sweden
| | - K.E. North
- Department of Epidemiology, Gillings
School of Global Public Health, University of North Carolina at Chapel Hill, Chapel
Hill, NC, USA
- Carolina Population Center,
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - U. Palotie
- Oral and Maxillofacial Diseases,
University of Helsinki and Helsinki University Hospital, Helsinki, Finland
| | - P.N. Papapanou
- Division of Periodontics, Section of
Oral, Diagnostic and Rehabilitation Sciences, Columbia University, College of Dental
Medicine, New York, NY, USA
| | - P.J. Pussinen
- Oral and Maxillofacial Diseases,
University of Helsinki and Helsinki University Hospital, Helsinki, Finland
- Institute of Dentistry, School on
Medicine, University of Eastern Finland, Kuopio, Finland
| | - D. Porteous
- Centre for Genomic and Experimental
Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh,
UK
| | - K. Reis
- Institute of Genomics, University of
Tartu, Tartu, Estonia
| | - A. Salminen
- Oral and Maxillofacial Diseases,
University of Helsinki and Helsinki University Hospital, Helsinki, Finland
| | - A.S. Schaefer
- Department of Periodontology, Oral
Medicine and Oral Surgery, Institute for Dental and Craniofacial Sciences,
Charité–Universitätsmedizin Berlin, Berlin, Germany
| | - T. Sudo
- Institute of Education, Tokyo Medical
and Dental University, Tokyo, Japan
| | - Y.Q. Sun
- Center for Oral Health Services and
Research Mid-Norway (TkMidt), Trondheim, Norway
- Department of Clinical and Molecular
Medicine, NTNU, Norwegian University of Science and Technology, Trondheim,
Norway
| | - A.L. Suominen
- Institute of Dentistry, School on
Medicine, University of Eastern Finland, Kuopio, Finland
- Institute of Dentistry, School on
Medicine, University of Eastern Finland, Kuopio, Finland
- Department of Oral and Maxillofacial
Diseases, Kuopio University Hospital, Kuopio, Finland
- Public Health Evaluation and
Projection Unit, Finnish Institute for Health and Welfare (THL), Helsinki,
Finland
| | - T. Tamahara
- Department of Community Medical
Supports, Tohoku Medical Megabank Organization, Tohoku University, Sendai,
Japan
| | - S.M. Weinberg
- Department of Human Genetics, Graduate
School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
- Center for Craniofacial and Dental
Genetics, Department of Oral and Craniofacial Sciences, School of Dental Medicine,
University of Pittsburgh, Pittsburgh, PA, USA
| | - P. Lundberg
- Department of Odontology, Section of
Molecular Periodontology, Umeå University, Umeå, Sweden
| | - M.L. Marazita
- Department of Human Genetics, Graduate
School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
- Center for Craniofacial and Dental
Genetics, Department of Oral and Craniofacial Sciences, School of Dental Medicine,
University of Pittsburgh, Pittsburgh, PA, USA
| | - I. Johansson
- Department of Odontology, Section of
Cariology, Umeå University, Umeå, Sweden
| |
Collapse
|
2
|
Suto H, Kamei K, Kato H, Misawa T, Unno M, Nitta H, Satoi S, Kawabata Y, Ohtsuka M, Rikiyama T, Sudo T, Matsumoto I, Hirao T, Okano K, Suzuki Y, Sata N, Isaji S, Sugiyama M, Takeyama Y. Diabetic control and nutritional status up to 1 year after total pancreatectomy: a nationwide multicentre prospective study. Br J Surg 2021; 108:e237-e238. [PMID: 33821972 DOI: 10.1093/bjs/znab097] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Revised: 01/20/2021] [Accepted: 02/18/2021] [Indexed: 01/09/2023]
Affiliation(s)
- H Suto
- Department of Gastroenterological Surgery, Kagawa University, Kagawa, Japan
| | - K Kamei
- Department of Surgery, Kindai University, Osaka, Japan
| | - H Kato
- Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Mie, Japan
| | - T Misawa
- Department of Surgery, The Jikei University Kashiwa Hospital, Chiba, Japan
| | - M Unno
- Department of Surgery, Tohoku University, Miyagi, Japan
| | - H Nitta
- Department of Surgery, Iwate Medical University, Iwate, Japan
| | - S Satoi
- Department of Surgery, Kansai Medical University, Osaka, Japan
| | - Y Kawabata
- Department of Digestive and General Surgery, Faculty of Medicine, Shimane University, Shimane, Japan
| | - M Ohtsuka
- Department of General Surgery, Chiba University, Chiba, Japan
| | - T Rikiyama
- Department of Surgery, Saitama Medical Centre, Jichi Medical University, Saitama, Japan
| | - T Sudo
- Department of Surgery, Kure Medical Centre and Chugoku Cancer Centre, Hiroshima, Japan
| | - I Matsumoto
- Department of Surgery, Kindai University, Osaka, Japan
| | - T Hirao
- Department of Public Health, Kagawa University, Kagawa, Japan
| | - K Okano
- Department of Gastroenterological Surgery, Kagawa University, Kagawa, Japan
| | - Y Suzuki
- Department of Gastroenterological Surgery, Kagawa University, Kagawa, Japan
| | - N Sata
- Department of Surgery, Jichi Medical University, Tochigi, Japan
| | - S Isaji
- Director of Mie University Hospital, Mie, Japan
| | - M Sugiyama
- Director of Tokyo Rosai Hospital, Tokyo, Japan
| | - Y Takeyama
- Department of Surgery, Kindai University, Osaka, Japan
| |
Collapse
|
3
|
Ogawa H, Sakai Y, Nishio W, Fujibayashi Y, Nishikubo M, Nishioka Y, Tane S, Kitamura Y, Sudo T, Sakuma Y, Yoshimura M. P1.12-23 DLL3 Is a Predictive Marker of Sensitivity to Adjuvant Chemotherapy for High-Grade Neuroendocrine Tumors. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
4
|
Toh U, Okabe M, Takao Y, Tanaka Y, Shigaki T, Takenaka M, Iwakuma N, Sudo T, Yamada A, Shichijo S, Itoh K, Akagi Y. Abstract P4-06-06: Comparison of the immunological and clinical effect of personalized peptide vaccination for patients with breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-06-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Selected therapeutic personalized peptide vaccines (PPV) were effective for boosting anticancer immune response that was associated with the clinical outcome as a prognostic factor for metastatic recurrent breast cancer (mrBC) 1-2. In this study, we investigated the immunological and clinical effect of PPV as the prophylactic cancer vaccine for non-recurrent but high-risk BC (nrhrBC) patients (pts), and we compared it's features to those of the mrBC pts who had active cancers or became resistant to the standard therapies(TR-mrBC). Methods: Material and Patient eligibility criteria: The peptides were selected from the 31 PPVs according to the results of HLA typing and peptide-specific IgG titers. Pts with a histological diagnosis of BC and their HLA-A molecules should be each of -A2, A3, A11, A24, A26, A31 or A33. The clinical protocols were approved by the institutional review board. (UMIN000003081and 00000184400000). Treatment schedule: A maximum of 4 peptides was administrated as weekly for initial four vaccinations and as biweekly for further inoculations. The concomitant standard endocrine therapy and the chemo-endocrine therapy were available for nrhrBC pts after finishing the standard adjuvant chemotherapy, and for mrBC pts concurrently. Immune and clinical response assessment: Specific T-cell responses, IgG titers and cytokines were evaluated using by interferon (IFN)-γ ELISPOT, Luminex assay and ELISA system in every 6-8 vaccinations. Toxicity, clinical response and correlation with the immune responses were investigated. Results: 16 pts with nrhrBC, 41 pts with mrBC and 79 pts with TR-mrBC received median 18, 16 and 14 vaccines, respectively. After PPV therapies, peptide-specific IgG and CTLs increased significantly in a total of 47 (77%) and 37(60%) in nrhrBC pts, 102 (63%) and 98 (61%) in mrBC pts, and 150(53%) and 100 (42%) in TR-mrBC pts. Pts experienced Grade 1-3 skin reaction at injection site, no other grade 3 or 4 SAEs were associated with PPV but with the disease progression or combination therapy. The median time to progression (TTP) and overall survival (OS) were not reached in nrhrBC pts, 7.8 and 29 months in mrBC pts, and were 7.5 and 15.9 months in TR-mrBC pts, respectively. The peptide specific CTL response was correlated significantly with OS in nrhrBC pts and the IgG levels were associated with the better OS in either non TR-mrBC pts or TR-mrBC pts. High levels of IL-6, GM-CSF, IFN-g, IL-2 receptor, BAFF were associated with worse prognosis for pts with TR-mrBC. And high levels of GM-CSF and BAFF were associated with worse prognosis for pts with nrhrBC and mrBC, respectively. In contrast, High levels of IL-2 were associated with the better prognosis for pts with mrBC. Conclusion: This study indicated that immunological features of these three groups were different from each other with most potent PPV-induced immune boosting for nrhrBC pts. Pts with mrBC who had lower immune-suppressive cytokine levels had the better prognosis. These results suggested the PPV therapy could be effective for postoperative prophylactic vaccination in patients with nrhrBC. References: 1. Takahashi R, Toh U, et al. Breast Cancer Res. 2014; 2. Toh U, Okabe M, et al. THE BREAST 2015.
Citation Format: Toh U, Okabe M, Takao Y, Tanaka Y, Shigaki T, Takenaka M, Iwakuma N, Sudo T, Yamada A, Shichijo S, Itoh K, Akagi Y. Comparison of the immunological and clinical effect of personalized peptide vaccination for patients with breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-06-06.
Collapse
Affiliation(s)
- U Toh
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - M Okabe
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - Y Takao
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - Y Tanaka
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - T Shigaki
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - M Takenaka
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - N Iwakuma
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - T Sudo
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - A Yamada
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - S Shichijo
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - K Itoh
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - Y Akagi
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| |
Collapse
|
5
|
Ueno M, Morizane C, Kawamoto Y, Takahashi H, Naruge D, Shimizu S, Nakamura K, Nakajima T, Kato T, Kudo T, Mizuno N, Ohtsubo K, Itoh S, Ishii H, Sudo T, Nomura S, Fujii S, Shitara K, Ohtsu A, Yoshino T. The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-screen: Efficient identification of cancer genome alterations in advanced biliary tract cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.100] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
6
|
Takayoshi K, Okamoto W, Hironaka S, Honma Y, Ebi H, Nakanishi R, Kajiwara T, Kudo T, Tamura T, Komatsu Y, Hara H, Naruge D, Moriwaki T, Miki I, Sudo T, Nomura S, Fujii S, Shitara K, Ohtsu A, Yoshino T. The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced small intestine cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
Naruge D, Morizane C, Ueno M, Takahashi H, Kawamoto Y, Sudo K, Shimizu S, Nakajima T, Itoh S, Ishii H, Kato T, Kudo T, Izumi M, Sudo T, Nomura S, Kuwata T, Fujii S, Shitara K, Ohtsu A, Yoshino T. The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced pancreatic cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx363.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Sudo T, Okada Y, Ozaki K, Urayama K, Kanai M, Kobayashi H, Gokyu M, Izumi Y, Tanaka T. Association of NOD2 Mutations with Aggressive Periodontitis. J Dent Res 2017; 96:1100-1105. [PMID: 28682159 DOI: 10.1177/0022034517715432] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Aggressive periodontitis (AgP) is characterized by rapid alveolar bone destruction and tooth loss early in life, and its etiology remains unclear. To explore the genetic risk factors of AgP, we performed genome-wide single-nucleotide polymorphism genotyping for identity-by-descent mapping and identified 32 distinct candidate loci, followed by whole exome sequencing with 2 pedigrees of AgP consisting of 3 cases and 1 control in 1 family and 2 sibling cases in the other. After variant filtering procedures and validation by targeted Sanger sequencing, we identified 2 missense mutations at 16q12 in NOD2 (p.Ala110Thr and p.Arg311Trp), which encodes nucleotide-binding oligomerization domain protein 2. We further examined 94 genetically unrelated AgP patients by targeted sequencing of NOD2 and found that 2 patients among them also carried the p.Arg311Trp variant. Furthermore, we found 3 additional missense mutations in this gene (p.His370Tyr, p.Arg459Cys, and p.Ala868Thr). These mutations either had not been previously observed or are extremely rare (frequency <0.001) in Asian populations. NOD2 plays a crucial role in innate immunity as an intracellular receptor initiating nuclear factor κB-dependent and mitogen-activated protein kinase-dependent gene transcription. These results demonstrated NOD2 as a novel gene involved in AgP.
Collapse
Affiliation(s)
- T Sudo
- 1 Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.,2 Department of Periodontology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| | - Y Okada
- 1 Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.,3 Department of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka University, Osaka, Japan
| | - K Ozaki
- 4 Laboratory for Medical Genome Sciences, Medical Genome Center, National Center for Geriatrics and Gerontology, Obu, Japan.,5 Laboratory for Cardiovascular Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - K Urayama
- 1 Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.,6 Center for Clinical Epidemiology, St. Luke's International University, Tokyo, Japan
| | - M Kanai
- 1 Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| | - H Kobayashi
- 2 Department of Periodontology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| | - M Gokyu
- 2 Department of Periodontology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| | - Y Izumi
- 2 Department of Periodontology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| | - T Tanaka
- 1 Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.,7 Bioresource Research Center, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
| |
Collapse
|
9
|
Yokobori T, Suzuki S, Miyazaki T, Sohda M, Sakai M, Tanaka N, Ozawa D, Hara K, Honjo H, Altan B, Fukuchi M, Ishii H, Iwatsuki M, Sugimachi K, Sudo T, Iwaya T, Nishida N, Mimori K, Kuwano H, Mori M. Intestinal epithelial culture under an air-liquid interface: a tool for studying human and mouse esophagi. Dis Esophagus 2016; 29:843-847. [PMID: 25809505 DOI: 10.1111/dote.12346] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
This study investigated whether an intestinal epithelial culture method can be applied to mouse and human esophageal cultures. The esophagi harvested from 1-day-old mice and adult humans were maintained in collagen gels. A commercially available culture medium for human embryonic stem cells was used for the human esophageal culture. We discovered that the intestinal epithelial culture method can be successfully applied to both mouse and human esophageal cultures. The long-term cultured esophageal organoids were rod-like luminal structures lined with myofibroblasts. We discovered that regeneration of the esophageal mucosal surface can be almost completely achieved in vitro, and the advantage of this method is that organoid cultures may be generated using host-derived fibroblasts as a niche. This method is a promising tool for mouse and human research in intestinal biology, carcinogenesis, and regenerative medicine.
Collapse
Affiliation(s)
- T Yokobori
- Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - S Suzuki
- Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - T Miyazaki
- Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - M Sohda
- Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - M Sakai
- Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - N Tanaka
- Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - D Ozawa
- Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - K Hara
- Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - H Honjo
- Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - B Altan
- Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - M Fukuchi
- Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - H Ishii
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan
| | - M Iwatsuki
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan
| | - K Sugimachi
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan
| | - T Sudo
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan
| | - T Iwaya
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan
| | - N Nishida
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan
| | - K Mimori
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan
| | - H Kuwano
- Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - M Mori
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
| |
Collapse
|
10
|
Sasaki H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. Br J Cancer 2014; 111:1275-84. [PMID: 25032731 PMCID: PMC4183840 DOI: 10.1038/bjc.2014.399] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 05/09/2014] [Accepted: 06/24/2014] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND The aim of this study was to investigate the predictive and prognostic values of intratumoural human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase subunit 1 (RRM1) expression in advanced cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy (AGC). METHODS Intratumoural hENT1 and RRM1 expression levels were investigated immunohistochemically in 127 patients with advanced cholangiocarcinoma who underwent surgical resection (68 with AGC and 59 without AGC). The impacts of hENT1 and RRM1 expression on survival were evaluated. RESULTS High intratumoural hENT1 and RRM1 expression levels were observed in 86 (68%) and 67 (53%) patients, respectively. In a multivariate analysis of 68 patients who received AGC, high hENT1 (P=0.044) and low RRM1 expression (P=0.009) were independently associated with prolonged disease-free survival (DFS), whereas low RRM1 expression (P=0.024) was independently associated with prolonged overall survival (OS). Moreover, concurrent high hENT1 and low RRM1 expression was a powerful independent predictor of prolonged DFS (P<0.001) and OS (P=0.001) when the combined classification of hENT1 and RRM1 was introduced. CONCLUSIONS Concurrent analysis of hENT1 and RRM1 expression may increase the predictive value of these biomarkers for survival of advanced cholangiocarcinoma patients treated with AGC.
Collapse
Affiliation(s)
- H Sasaki
- Department of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan
| | - Y Murakami
- Department of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan
| | - K Uemura
- Department of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan
| | - T Sudo
- Department of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan
| | - Y Hashimoto
- Department of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan
| | - N Kondo
- Department of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan
| | - T Sueda
- Department of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan
| |
Collapse
|
11
|
Takahashi Y, Sawada G, Kurashige J, Uchi R, Matsumura T, Ueo H, Takano Y, Eguchi H, Sudo T, Sugimachi K, Yamamoto H, Doki Y, Mori M, Mimori K. Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer 2013; 110:164-71. [PMID: 24196785 PMCID: PMC3887297 DOI: 10.1038/bjc.2013.698] [Citation(s) in RCA: 242] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2013] [Revised: 10/08/2013] [Accepted: 10/11/2013] [Indexed: 12/16/2022] Open
Abstract
Background: We previously conducted gene expression microarray analyses to identify novel indicators for colorectal cancer (CRC) metastasis and prognosis from which we identified PVT-1 as a candidate gene. PVT-1, which encodes a long noncoding RNA, mapped to chromosome 8q24 whose copy-number amplification is one of the most frequent events in a wide variety of malignant diseases. However, PVT-1 molecular mechanism of action remains unclear. Methods: We conducted cell proliferation and invasion assays using colorectal cancer cell lines transfected with PVT-1siRNA or negative control siRNA. Gene expression microarray analyses on these cell lines were also carried out to investigate the molecular function of PVT-1. Further, we investigated the impact of PVT-1 expression on the prognosis of 164 colorectal cancer patients by qRT–PCR. Results: CRC cells transfected with PVT-1 siRNA exhibited significant loss of their proliferation and invasion capabilities. In these cells, the TGF-β signalling pathway and apoptotic signals were significantly activated. In addition, univariate and multivariate analysis revealed that PVT-1 expression level was an independent risk factor for overall survival of colorectal cancer patients. Conclusion: PVT-1, which maps to 8q24, generates antiapoptotic activity in CRC, and abnormal expression of PVT-1 was a prognostic indicator for CRC patients.
Collapse
Affiliation(s)
- Y Takahashi
- 1] Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan [2] Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Japan
| | - G Sawada
- 1] Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan [2] Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Japan
| | - J Kurashige
- Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan
| | - R Uchi
- Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan
| | - T Matsumura
- 1] Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan [2] Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Japan
| | - H Ueo
- Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan
| | - Y Takano
- Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan
| | - H Eguchi
- Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan
| | - T Sudo
- Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan
| | - K Sugimachi
- Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan
| | - H Yamamoto
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Japan
| | - Y Doki
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Japan
| | - M Mori
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Japan
| | - K Mimori
- Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan
| |
Collapse
|
12
|
Ohge H, Watadani Y, Uegami S, Shigemoto N, Kondo N, Hashimoto Y, Sudo T, Uemura K, Murakami Y, Sueda T. P74 Antibiotic prophylaxis in the era of drug-resistant Bacteroides genus. Int J Antimicrob Agents 2013. [DOI: 10.1016/s0924-8579(13)70319-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
13
|
Tokunaga T, Narushima T, Yonezawa T, Sudo T, Okubo S, Komatsubara S, Sasaki K, Yamamoto T. Temperature distributions of electron beam-irradiated samples by scanning electron microscopy. J Microsc 2012; 248:228-33. [PMID: 23062061 DOI: 10.1111/j.1365-2818.2012.03666.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
An electron beam (EB) generated by a scanning electron microscope (SEM) was used to irradiate two samples having different thermal conductivities, and the resulting temperatures of the EB-irradiated areas as well as the temperature distributions within the samples were then measured using a thermal camera. These measurements showed overall increases in sample temperatures, as well as revealed temperature rises at the EB-irradiated areas that had little difference with one of the theoretical predictions. Differences between the actual and the predicted temperature measurements were analysed in terms of the accuracy with which parameters could be estimated. The temperature distributions of the samples were measured and, On the basis of the results, it was hypothesized that the temperature differential over an irradiated sample will be inversely correlated with its thermal conductivity.
Collapse
Affiliation(s)
- T Tokunaga
- Department of Quantum Engineering, Nagoya University, Furo-cho, chikusa-ku, Nagoya, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Shimodaira H, Soeda H, Gamoh M, Andoh H, Yamaguchi T, Watanabe M, Ishobe H, Sudo T, Kato S, Ishioka C. Prospective Trial of Cetuximab Plus Irinotecan for Oxaliplatin and Irinotecan-Based Chemotherapy-Refractory Patients Advanced and/or Metastatic Colorectal Cancer, Evaluation of the Efficacy and Safety Based on Mutation Status of the EGFR Related Genes. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32330-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
15
|
Shiomi A, Ito M, Saito N, Hirai T, Ohue M, Kubo Y, Takii Y, Sudo T, Kotake M, Moriya Y. The indications for a diverting stoma in low anterior resection for rectal cancer: a prospective multicentre study of 222 patients from Japanese cancer centers. Colorectal Dis 2011; 13:1384-9. [PMID: 20977591 DOI: 10.1111/j.1463-1318.2010.02481.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
AIM The aim of the study was to determine the present state of diverting stoma construction in Japanese cancer centres and to investigate the relationship between symptomatic leakage and diverting stoma after low anterior resection for rectal cancer. METHOD Two hundred and twenty-two consecutive patients undergoing low anterior resection for rectal cancer located within 10 cm from the anal verge were investigated in a prospective, multicenter study. RESULTS The overall leakage rate was 9.0% (20/222). Of 31 cases with an anastomosis within 2.0 cm from the anal verge, 22 (71%) had a diverting stoma. Of cases anastomosed within 5.0 cm, the absence of a diverting stoma and tumour size were significantly related to an increased rate of leakage [leakage in 13 (12.7%) of 102 cases without a diverting stoma; in three (3.8%) of 80 cases with a diverting stoma]. Among anastomoses within 2.0 cm from the anal verge, leakage occurred in four (44.4%) of nine cases without and in none (0%) of 22 cases with a diverting stoma. CONCLUSION We recommend a diverting stoma for an anastomosis within 5.0 cm of the anal verge and strongly recommend it for a very low anastomosis within 2.0 cm.
Collapse
Affiliation(s)
- A Shiomi
- Division of Colorectal Surgery, Shizuoka Cancer Center Hospital, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Ota Y, Sudo T, Tsujino K, Iwae S, Ohbayashi C, Soejima T. P16/INK4a Downregulation Is A Possible Trigger for Human Papillomavirus-associated Metachronous Head and Neck Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.1171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
17
|
Shimodaira H, Soeda H, Gamoh M, Andoh H, Yamaguchi T, Watanabe M, Isobe H, Sudo T, Kato S, Ishioka C. Phase II trial of cetuximab plus irinotecan for FOLFOX and FOLFIRI-refractory patients with EGFR-positive advanced and/or metastatic colorectal cancer: Evaluation of the efficacy and safety based on KRAS mutation status (T- CORE0801). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
573 Background: Activating mutation of the KRAS gene is a predictive biomarker for loss of efficacy to anti-EGFR antibody therapy. However, this was mainly established by the evidences of Caucasian studies. Then, this prospective study investigated the role of KRAS mutations on efficacy and safety to cetuximab plus irinotecan in Japanese patients with metastatic colorectal cancer (mCRC). Methods: We conducted a prospective study to analyze objective response to cetuximab plus irinotecan in molecularly defined KRAS wild-type (WT) or mutant subgroups of chemotherapy-refractory mCRC. KRAS mutations were detected by direct sequence on DNA from formalin-fixed, paraffin-embedded tissue of patients treated in 11 centers in Japan. Additional EGFR related genes such as BRAF, PIK3CA etc. and antibody-dependent cellular cytotoxicity related polymorphism in FCγRIIa and RIIIa genes were also examined. Results: Forty-three patients were enrolled. KRAS mutations were found in 31.7% of 41 eligible patients. Response rate (RR) to cetuximab plus irinotecan, the primary endpoint of the study, was 17.9% and 0% for the patients with tumor harboring WT and mutant KRAS, respectively. No significant differences in toxicity were observed between the KRAS WT and mutant groups. Detail statistical analyses are ongoing. Conclusions: We confirmed that KRAS status is a useful predictive maker for the efficacy to cetuximab plus irinotecan therapy in Japanese mCRC patients, even though the response rate in the KRAS WT group was lower than expected. [Table: see text]
Collapse
Affiliation(s)
- H. Shimodaira
- Tohoku University, Sendai, Japan; South Miyagi Medical Center, Ohgawara-Machi, Japan; Nakadori General Hospital, Akita, Japan; Yamagata University, Yamagata, Japan; Yamagata Prefectural Central Hospital, Yamagata, Japan
| | - H. Soeda
- Tohoku University, Sendai, Japan; South Miyagi Medical Center, Ohgawara-Machi, Japan; Nakadori General Hospital, Akita, Japan; Yamagata University, Yamagata, Japan; Yamagata Prefectural Central Hospital, Yamagata, Japan
| | - M. Gamoh
- Tohoku University, Sendai, Japan; South Miyagi Medical Center, Ohgawara-Machi, Japan; Nakadori General Hospital, Akita, Japan; Yamagata University, Yamagata, Japan; Yamagata Prefectural Central Hospital, Yamagata, Japan
| | - H. Andoh
- Tohoku University, Sendai, Japan; South Miyagi Medical Center, Ohgawara-Machi, Japan; Nakadori General Hospital, Akita, Japan; Yamagata University, Yamagata, Japan; Yamagata Prefectural Central Hospital, Yamagata, Japan
| | - T. Yamaguchi
- Tohoku University, Sendai, Japan; South Miyagi Medical Center, Ohgawara-Machi, Japan; Nakadori General Hospital, Akita, Japan; Yamagata University, Yamagata, Japan; Yamagata Prefectural Central Hospital, Yamagata, Japan
| | - M. Watanabe
- Tohoku University, Sendai, Japan; South Miyagi Medical Center, Ohgawara-Machi, Japan; Nakadori General Hospital, Akita, Japan; Yamagata University, Yamagata, Japan; Yamagata Prefectural Central Hospital, Yamagata, Japan
| | - H. Isobe
- Tohoku University, Sendai, Japan; South Miyagi Medical Center, Ohgawara-Machi, Japan; Nakadori General Hospital, Akita, Japan; Yamagata University, Yamagata, Japan; Yamagata Prefectural Central Hospital, Yamagata, Japan
| | - T. Sudo
- Tohoku University, Sendai, Japan; South Miyagi Medical Center, Ohgawara-Machi, Japan; Nakadori General Hospital, Akita, Japan; Yamagata University, Yamagata, Japan; Yamagata Prefectural Central Hospital, Yamagata, Japan
| | - S. Kato
- Tohoku University, Sendai, Japan; South Miyagi Medical Center, Ohgawara-Machi, Japan; Nakadori General Hospital, Akita, Japan; Yamagata University, Yamagata, Japan; Yamagata Prefectural Central Hospital, Yamagata, Japan
| | - C. Ishioka
- Tohoku University, Sendai, Japan; South Miyagi Medical Center, Ohgawara-Machi, Japan; Nakadori General Hospital, Akita, Japan; Yamagata University, Yamagata, Japan; Yamagata Prefectural Central Hospital, Yamagata, Japan
| | | |
Collapse
|
18
|
Hashimoto H, Sudo T, Maruta H, Nishimura R. The direct PAK1 inhibitor, TAT-PAK18, blocks preferentially the growth of human ovarian cancer cell lines in which PAK1 is abnormally activated by autophosphorylation at Thr 423. Drug Discov Ther 2010; 4:1-4. [PMID: 22491145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
So far no effective therapeutic has been developed for the FDA-approved treatment of ovarian cancer patients. Recently we provided the first evidence indicating that an old antibiotic (antiparasitic drug) called Ivermectin suppresses the growth of a variety of human ovarian cancer cell lines in vitro by inactivating the oncogenic kinase PAK1 somehow (Hashimoto H, et al. Drug Discov Ther. 2009;3:243-246). This kinase is now known to be essential for the growth of more than 70% of all human cancers including breast, prostate, pancreatic, colon, gastric, lung, cervical, thyroid cancers as well as hepatoma, glioma, melanoma, MM (multiple myeloma) and NF (neurofibromatosis) tumors. In this study, using the cell-permeable PAK1-inactivating peptide TAT-PAK18 which blocks the essential PAK1-PIX interaction, we examined the relationship between the sensitivity of ovarian cancer cell lines to this anti-PAK1 peptide and the protein expression/autophosphorylation levels of PAK1 in these cell lines, and found that the more PAK1 is abnormally activated (autophosporylated at Thr 423), the more their growth is sensitive to this peptide, regardless of their PAK1 expression levels. This observation provides the first direct evidence that ovarian cancers also belong to the PAK1-dependent cancers which represent more than 70% of all human cancers, suggesting that anti-PAK1 drugs would be effective therapeutics for ovarian cancers.
Collapse
|
19
|
Hashimoto H, Messerli SM, Sudo T, Maruta H. Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines. Drug Discov Ther 2009; 3:243-246. [PMID: 22495656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Ivermectin is an old anti-parasitic antibiotic which selectively kills nematodes at a very low dose (0.2 mg/kg) by inhibiting their GABA (gamma-aminobutyric acid) receptor, but not mammalian counterpart. Interestingly, several years ago it was reported by a Russian group that Ivermectin can suppress almost completely the growth of human melanoma and a few other cancer xenografts in mice at the much higher doses (3-5 mg/kg) without any adverse effect on mice. However, its anti-cancer mechanism still remained to be clarified at the molecular levels, that would determine the specific type of cancers susceptible to this drug. The first hint towards its anti-PAK1 potential was a recent finding that Ivermectin at its sublethal doses dramatically reduces the litter size (number of eggs laid) of the tiny nematode C. elegans. Interestingly, either a PAK1-deficiency (gene knock-out) or treatment with natural anti-PAK1 products such as CAPE (caffeic acid phenethyl ester) and ARC (artepillin C), the major anti-cancer ingredients in propolis, also causes the exactly same effect on this nematode, suggesting the possibility that the kinase PAK1 might be a new target of Ivermectin. This kinase is required for the growth of more than 70% of human cancers such as pancreatic, colon, breast and prostate cancers and NF (neurofibromatosis) tumors. Here we demonstrate for the first time that Ivermectin blocks the oncogenic kinase PAK1 in human ovarian cancer and NF2-deficient Schwannoma cell lines to suppress their PAK1-dependent growth in cell culture, with the IC50 between 5-20 μM depending on cell lines.
Collapse
|
20
|
Kawai K, Saito A, Sudo T, Osada H. Specific Regulation of Cytokine-Dependent p38 MAP Kinase Activation by p62/SQSTM1. J Biochem 2007; 143:765-72. [DOI: 10.1093/jb/mvn027] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
|
21
|
Nishimura S, Tsuda H, Ito K, Kita T, Terai Y, Sudo T, Jobo T, Kigawa J, Sugiyama T, Yaegashi N. Hypoxia-inducible protein 2 (HIG2) as a new biomarker of ovarian clear cell adenocarcinoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.16001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
16001 Background: Epithelial ovarian cancer (EOC) can be subclassified into five major histologic types (Serous(SC), Mucinous(MC), Endometrioid(EC), Clear cell(CC), Undifferentiated (UC)). Among them, CC generally has a poor response to combination chemotherapy and its overall prognosis is poorer, as compared with other histologic types. In previous reports, we compared gene expression profiles in CC and SC using cDNA microarrays and suggested that HIG2 gene might be a new biomarker for CC (Clin Cancer Res, 2005). In this study, we generated a polyclonal antibody for HIG2 and further validated the expression of HIG2 in EOC. In addition, HIG2 expression was evaluated in CC derived from endometrium(EMCC) and kidney(KDCC). Methods: Formalin-fixed surgical samples from 254 EOC, 17 EMCC and 29 KDCC patients were included in this study. HIG2 expression was investigated by immunohistochemistry. HIG2 cytoplasmic staining were divided into positive or negative. Results: Histologic types and stages of EOC were as followed: (SC: 51; MC: 25; EC: 31; CC: 130; UC: 17) and (I: 96; II: 37; III: 100; IV: 21). In EOC, 175 of 254(69%) cases had HIG2 expression. The relationship between HIG2 expression and histologic types was shown in table . The positive rate of HIG2 in CC was significantly higher than other histologic types in EOC. However, there is no significant correlation between HIG2 expression and stages or grades. In addition, both CC of the ovary and endometrium showed significantly higher levels of HIG2 expression compared to those of CC of the kidney. Conclusions: HIG2 expression is a new biomarker for CC. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Nishimura
- Osaka City General Hospital, Osaka, Japan; Tohoku University Graduate School of Medicine, Sendai, Japan; National Defense Medical College, Tokorozawa, Japan; Osaka Medical College, Takatsuki, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Kitasato University, Sagamihara, Japan; Tottori University School of Medicine, Yonago, Japan; Iwate Medical University, Morioka, Japan
| | - H. Tsuda
- Osaka City General Hospital, Osaka, Japan; Tohoku University Graduate School of Medicine, Sendai, Japan; National Defense Medical College, Tokorozawa, Japan; Osaka Medical College, Takatsuki, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Kitasato University, Sagamihara, Japan; Tottori University School of Medicine, Yonago, Japan; Iwate Medical University, Morioka, Japan
| | - K. Ito
- Osaka City General Hospital, Osaka, Japan; Tohoku University Graduate School of Medicine, Sendai, Japan; National Defense Medical College, Tokorozawa, Japan; Osaka Medical College, Takatsuki, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Kitasato University, Sagamihara, Japan; Tottori University School of Medicine, Yonago, Japan; Iwate Medical University, Morioka, Japan
| | - T. Kita
- Osaka City General Hospital, Osaka, Japan; Tohoku University Graduate School of Medicine, Sendai, Japan; National Defense Medical College, Tokorozawa, Japan; Osaka Medical College, Takatsuki, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Kitasato University, Sagamihara, Japan; Tottori University School of Medicine, Yonago, Japan; Iwate Medical University, Morioka, Japan
| | - Y. Terai
- Osaka City General Hospital, Osaka, Japan; Tohoku University Graduate School of Medicine, Sendai, Japan; National Defense Medical College, Tokorozawa, Japan; Osaka Medical College, Takatsuki, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Kitasato University, Sagamihara, Japan; Tottori University School of Medicine, Yonago, Japan; Iwate Medical University, Morioka, Japan
| | - T. Sudo
- Osaka City General Hospital, Osaka, Japan; Tohoku University Graduate School of Medicine, Sendai, Japan; National Defense Medical College, Tokorozawa, Japan; Osaka Medical College, Takatsuki, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Kitasato University, Sagamihara, Japan; Tottori University School of Medicine, Yonago, Japan; Iwate Medical University, Morioka, Japan
| | - T. Jobo
- Osaka City General Hospital, Osaka, Japan; Tohoku University Graduate School of Medicine, Sendai, Japan; National Defense Medical College, Tokorozawa, Japan; Osaka Medical College, Takatsuki, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Kitasato University, Sagamihara, Japan; Tottori University School of Medicine, Yonago, Japan; Iwate Medical University, Morioka, Japan
| | - J. Kigawa
- Osaka City General Hospital, Osaka, Japan; Tohoku University Graduate School of Medicine, Sendai, Japan; National Defense Medical College, Tokorozawa, Japan; Osaka Medical College, Takatsuki, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Kitasato University, Sagamihara, Japan; Tottori University School of Medicine, Yonago, Japan; Iwate Medical University, Morioka, Japan
| | - T. Sugiyama
- Osaka City General Hospital, Osaka, Japan; Tohoku University Graduate School of Medicine, Sendai, Japan; National Defense Medical College, Tokorozawa, Japan; Osaka Medical College, Takatsuki, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Kitasato University, Sagamihara, Japan; Tottori University School of Medicine, Yonago, Japan; Iwate Medical University, Morioka, Japan
| | - N. Yaegashi
- Osaka City General Hospital, Osaka, Japan; Tohoku University Graduate School of Medicine, Sendai, Japan; National Defense Medical College, Tokorozawa, Japan; Osaka Medical College, Takatsuki, Japan; Hyogo Medical Center for Adults, Akashi, Japan; Kitasato University, Sagamihara, Japan; Tottori University School of Medicine, Yonago, Japan; Iwate Medical University, Morioka, Japan
| |
Collapse
|
22
|
Tanaka T, Ohki N, Kojima A, Maeno Y, Miyahara Y, Sudo T, Takekida S, Yamaguchi S, Sasaki H, Nishimura R. Radiotherapy negates the effect of retroperitoneal nonclosure for prevention of lymphedema of the legs following pelvic lymphadenectomy for gynecological malignancies: an analysis from a questionnaire survey. Int J Gynecol Cancer 2007; 17:460-4. [PMID: 17316358 DOI: 10.1111/j.1525-1438.2007.00869.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Using patient questionnaires, we studied the long-term effect of leaving the peritoneum open on the incidence of lymphedema of the legs in patients following pelvic lymphadenectomy for gynecological malignancies. The patients were retrospectively assigned to one of two groups, depending on whether the retroperitoneum was closed or left open at surgery. Three years after surgery, we obtained valid questionnaire responses from 101 patients (43 cervical, 46 endometrial, and 12 ovarian cancers) in the closure group and 83 patients (34 cervical, 40 endometrial, and 9 ovarian cancers) in the nonclosure group. In patients' self-analysis, the overall incidence of lymphedema of the legs was significantly lower in the nonclosure group than in the closure group (25.3% and 50.5%, respectively; P < 0.01). The incidence of lymphedema of the legs was significantly increased by postoperative radiotherapy. Especially in the nonclosure group, the incidence of lymphedema was only 15.8% in patients who did not have radiotherapy, but it increased significantly (44.4%) (P < 0.05) when patients underwent radiotherapy. In conclusion, this questionnaire survey suggested that leaving the retroperitoneum open after lymphadenectomy is significantly effective in reducing the incidence of leg lymphedema, which impairs patients' quality of life more than expected by physicians.
Collapse
Affiliation(s)
- T Tanaka
- Department of Gynecology, Hyogo Medical Center for Adults, Akashi, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Sudo T, Mimori K, Nagahara H, Utsunomiya T, Fujita H, Tanaka Y, Shirouzu K, Inoue H, Mori M. Identification of EGFR mutations in esophageal cancer. Eur J Surg Oncol 2006; 33:44-8. [PMID: 17142003 DOI: 10.1016/j.ejso.2006.10.034] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2006] [Accepted: 10/20/2006] [Indexed: 10/23/2022] Open
Abstract
BACKGROUND It is well known that the prognosis for esophageal cancer is worse than for other digestive cancers in spite of multimodality treatment, and there is an urgent need to improve this situation. The epidermal growth factor receptor (EGFR) inhibitor, gefitinib, was approved in Japan to treat advanced non-small cell lung cancer patients and several papers have since reported that the successfully treated patients had genetic mutations in EGFR. PURPOSE The aim of this study was to investigate the existence of EGFR mutations in esophageal cancer cell lines and primary lesions, and also to explore the possibility of treating esophageal cancer using gefitinib. MATERIALS AND METHODS Nineteen esophageal cancer cell lines were cultured and DNA was extracted using an ultracentrifugation method. Fifty cases of primary cancer and corresponding normal tissue samples were obtained and DNA was extracted using the same protocol. Nested PCR and DNA sequencing targeting exons 18, 19, 20 and 21 of EGFR were performed to investigate the presence of mutations in esophageal cancer cell lines and primary tumors. RESULTS Three of the 19 cell lines had the same silent mutation at nucleotide 2607, a G-to-A substitution in exon 20. One of the 50 patients had an EGFR mutation in codon 719, resulting in an amino acid substitution from glycine to aspartic acid. CONCLUSION EGFR mutations in esophageal carcinoma are rare but do exist, and thus gefitinib could be included in esophageal cancer treatment regimens by selecting those patients who possess such mutations.
Collapse
Affiliation(s)
- T Sudo
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumihara, Beppu 874-0838, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Hashimoto K, Sudo T, Hirano M, Motomura H, Tagawa K, Nashiro S, Uemura K, Yoshimoto S. Efficacy and safety of zotepine for patients with treatment-resistant schizophrenia. Schizophr Res 2006; 87:332-3. [PMID: 16797164 DOI: 10.1016/j.schres.2006.03.048] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2005] [Revised: 03/27/2006] [Accepted: 03/27/2006] [Indexed: 10/24/2022]
|
25
|
Itamochi H, Yamasaki F, Sudo T, Takahashi T, Bartholomeusz C, Das S, Terakawa N, Ueno NT. Reduction of radiation-induced apoptosis by specific expression of Bcl-2 in normal cells. Cancer Gene Ther 2005; 13:451-9. [PMID: 16294215 DOI: 10.1038/sj.cgt.7700920] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Radiation-induced apoptosis is thought to underlie the toxicity of radiation to normal tissues as well as to cancer cells. We hypothesized that specific ectopic overexpression of the antiapoptotic molecule Bcl-2 in normal cells would inhibit radiation-induced apoptosis and thereby reduce radiation-induced toxicity in normal cells. To express Bcl-2 specifically in normal cells (which have wild-type (wt) p53) but not in cancer cells (which often have mutated p53), we constructed a Bcl-2 expression plasmid (PG13-Bcl-2) with a minimal promoter regulated by multiple wt p53 DNA-binding sites and found that the presence of wt p53 protein strongly upregulated Bcl-2 expression through this plasmid. Transfection of NIH 3T3 fibroblasts, which express wt p53, with PG13-Bcl-2 increased cell survival and reduced apoptosis; however, transfection of MDA-MB-231 breast cancer cells, which have mutated p53, did not affect survival and apoptosis of those cells. These results indicate that irradiation of normal cells rapidly upregulates the expression of wt p53, which binds to the p53 binding sequence of the PG13-Bcl-2 plasmid and increases the transcriptional activity of Bcl-2. Ectopic expression of Bcl-2 reduced radiation-induced apoptosis only in normal cells (not in cancer cells). Bcl-2 expression was detected in the lung from mice injected via a tail vein with LPD-PG13-Bcl-2 or LPD-CMV-Bcl-2, but did not in the lung from mice treated with DOTAP or LPD-PG13-mock. This novel approach to inhibiting radiation-induced apoptosis in normal cells may allow such cells to be protected from radiation-induced toxicity. Further preclinical in vivo studies are needed.
Collapse
Affiliation(s)
- H Itamochi
- Breast Cancer Translational Research Laboratory, Houston, TX, USA
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, Inoue H, Wakiyama S, Fujita H, Shirouzu K, Mori M. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 2005; 92:1754-8. [PMID: 15856046 PMCID: PMC2362028 DOI: 10.1038/sj.bjc.6602531] [Citation(s) in RCA: 186] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Enhancer of zeste homologue 2 (EZH2), a member of the polycomb group protein family, plays a crucial role in the regulation of embryonic development and has been associated with the regulation of the cell cycle. Recently, several studies have shown that EZH2 is highly expressed in aggressive tumours, including human breast cancer, prostate cancer, and lymphomas. We thus analysed EZH2 expression using real-time reverse transcription-polymerase chain reaction, and correlated its expression status with various clinicopathological parameters in 66 patients with hepatocellular carcinoma (HCC). We found high expression of EZH2 in human liver cancer cell lines. Furthermore, EZH2 gene-expression levels in tumour tissue specimens (0.34+/-0.52) were significantly higher (P<0.0001) than those in the corresponding nontumour tissue specimens (0.07+/-0.09). The incidence of cancer cell invasion into the portal vein was significantly higher (P<0.001) in the high EZH2 expression group (26 of the 33, 79%) than in the low expression group (13 of the 33, 39%). However, there was no significant difference in the disease-free survival rate between the two groups. The findings of this study indicate that EZH2 mRNA expression was upregulated in human HCC and may play an important role in tumour progression, especially by facilitating portal vein invasion.
Collapse
Affiliation(s)
- T Sudo
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546, Tsurumihara, Beppu 874-0838, Japan
- Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan
| | - T Utsunomiya
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546, Tsurumihara, Beppu 874-0838, Japan
| | - K Mimori
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546, Tsurumihara, Beppu 874-0838, Japan
| | - H Nagahara
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546, Tsurumihara, Beppu 874-0838, Japan
| | - K Ogawa
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546, Tsurumihara, Beppu 874-0838, Japan
| | - H Inoue
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546, Tsurumihara, Beppu 874-0838, Japan
| | - S Wakiyama
- Department of Surgery, Iizuka Hospital, 3-83 Yoshio-machi, Iizuka 820-8505, Japan
| | - H Fujita
- Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan
| | - K Shirouzu
- Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan
| | - M Mori
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546, Tsurumihara, Beppu 874-0838, Japan
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546, Tsurumihara, Beppu 874-0838, Japan. E-mail:
| |
Collapse
|
27
|
Mimori K, Ogawa K, Okamoto M, Sudo T, Inoue H, Mori M. Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur J Surg Oncol 2005; 31:376-80. [PMID: 15837043 DOI: 10.1016/j.ejso.2004.11.001] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2004] [Revised: 10/21/2004] [Accepted: 11/03/2004] [Indexed: 11/29/2022] Open
Abstract
INTRODUCTION Enhancer of zeste homolog 2 (EZH-2) is a polycomb group (PcG) protein, and the clinical significance of this protein has not yet been determined in colorectal cancer (CRC) cases. Recently, investigations of CRC cases have focused on the interaction between EZH-2 and histone deacetylase-1 (HDAC-1). PATIENTS AND METHODS We performed real time RT-PCR to evaluate the expression of EZH-2 mRNA quantitatively in tumour and normal tissue samples from 61 cases of CRC. The expression of HDAC-1 in CRC cases was also examined in order to compare its levels with those of EZH-2. RESULTS Among the CRC cases, 32 patients whose tumour tissue showed overexpression of EZH-2 also had a significantly worse prognosis than did 29 patients whose tumour tissue showed low EZH-2 expression (p<0.05). In addition, a significant correlation between EZH-2 and HDAC-1 expression was observed in 61 CRC cases (p<0.05). Moreover, 20 cases of both high EZH-2 and high HDAC-1 expression showed poor prognoses than did 19 cases in which there was low EZH-2 and low HDAC-1 expression (p<0.05). CONCLUSION The abundant expression of EZH-2 in CRC cases indicated that EZH-2 may be an oncogene and a prognostic marker for CRC cases. We discovered there was concordant expression of HDAC-1 with EZH-2 in clinical CRC cases, in addition to the fact that higher expression levels of both genes predicted a poor prognosis.
Collapse
Affiliation(s)
- K Mimori
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546 Tsrumihara, Beppu 874-0838, Japan
| | | | | | | | | | | |
Collapse
|
28
|
|
29
|
Daitoku K, Takahashi K, Sudo T. [Ruptured thoracic aortic aneurysm presenting as massive epistaxis; report of a case]. Kyobu Geka 2004; 57:398-401. [PMID: 15151043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
An 80-year-old woman was transported to the emergency room at our hospital by the ambulance, suffering from massive epistaxis. As the patient was hemodynamically stable, otolaryngologist attempted to perform tamponade using nasal packing. However, the patient's condition deteriorated, with the development of dyspnea and a reduction in oxygen saturation to 90%. A chest X-ray performed at this point revealed left lung consolidation and pleural effusion while chest computed tomography (CT) demonstrated that rupture of a descending aortic aneurysm with periaortic hematoma and extension of hemorrhage into the left lower lobe of the lung. Emergency surgery was performed under partial extracorporeal circulation, established by cannulation of the right femoral artery and vein. In addition to the replacement of the descending aorta with a prosthetic conduit, left lower lobectomy was necessary because of severe adhesion to the descending aorta. The postoperative course was largely uncomplicated apart from development of chylothorax, which resolved with a short period of total parenteral nutrition and she was discharged 50 days after surgery.
Collapse
Affiliation(s)
- K Daitoku
- Department of Cardiovascular Surgery, Aomori Rosai Hospital, Hachinohe, Japan
| | | | | |
Collapse
|
30
|
Abstract
A 73-year-old woman complaining of sudden hoarseness visited our hospital 17 days after the onset. The upper gastrointestinal contrast study showed a shallow ulcer crater with moderate bulging in the upper thoracic esophagus. Endoscope and computed tomography revealed an esophageal foreign body, a Press Through Pack (PTP), in the esophageal ulcer. The PTP could be removed endoscopically. Two months after extraction of the PTP, the patient was taking normal food orally and was discharged. The esophageal perforation, looking like a diverticle, was still present more than 1 year after the onset.
Collapse
Affiliation(s)
- T Sudo
- Department of Surgery, Kurume University School of Medicine, Kurume-city, Fukuoka, Japan
| | | | | | | | | |
Collapse
|
31
|
Murata K, Sudo T, Kameyama M, Fukuoka H, Muka M, Doki Y, Sasaki Y, Ishikawa O, Kimura Y, Imaoka S. Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility. Clin Exp Metastasis 2002; 18:599-604. [PMID: 11688965 DOI: 10.1023/a:1011926116777] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
To investigate mechanisms for regulation of intracellular cAMP involved in cancer cell invasion, phosphodiesterase (PDE) activity in a colon cancer cell line, DLD-1, was studied. Activities of PDE 2, 4, and 5 were detected in DLD-1 cells by pharmacological approach. Specific and cell permeable inhibitors for those PDEs were used to determine which PDE is responsible for cAMP turnover involved in cancer cell motility. Treatment of DLD-1 cells with rolipram and Ro-20-1724 inhibitors for PDE 4, elevated intracellular cAMP contents three to five times of control. EHNA, an inhibitor for PDE 2, and zaprinast. an inhibitor for PDE 5, did not affect cAMP levels. To assess cellular motility, we utilized chemotaxis assay. EHNA and zaprinast did not suppress serum-induced chemotaxis. In contrast, rolipram and Ro-20-1724, suppressed chemotaxis in a dose dependent fashion. These suggest that PDE 4 plays a critical role in regulating intracellular cAMP levels of colon cancer cells and is involved in cancer invasion. PDE 4 can be a novel target of anti-invasion drug.
Collapse
Affiliation(s)
- K Murata
- Department of Surgical Oncology, Osaka Medical Center for Cancer and CVD, Higashinari, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Sano H, Yokode M, Takakura N, Takemura G, Doi T, Kataoka H, Sudo T, Nishikawa S, Fujiwara H, Nishikawa SI, Kita T. Study on PDGF receptor beta pathway in glomerular formation in neonate mice. Ann N Y Acad Sci 2001; 947:303-5. [PMID: 11795278 DOI: 10.1111/j.1749-6632.2001.tb03951.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The assembly of vascular endothelial cells (ECs) and smooth muscle cells is a critical event in the development of the cardiovascular system. Although the role of ECs in this event has been studied intensively, the cross-talk between the two cell components remains poorly understood. In this study, we blocked platelet-derived growth factor receptor (PDGFR) pathways in mice by antagonistic rat monoclonal antibody APB5 against murine PDGFR-beta and examined glomerular capillary formation.
Collapse
Affiliation(s)
- H Sano
- Department of Geriatric Medicine, Graduate School of Medicine, Kyoto University, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Takanami-Ohnishi Y, Asada S, Tsunoda H, Fukamizu A, Goto K, Yoshikawa H, Kubo T, Sudo T, Kimura S, Kasuya Y. Possible involvement of p38 mitogen-activated protein kinase in decidual function in parturition. Biochem Biophys Res Commun 2001; 288:1155-61. [PMID: 11700032 DOI: 10.1006/bbrc.2001.5895] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We designed the present study to elucidate the molecular mechanism for parturition, focusing on p38 mitogen-activated protein kinase (p38). The kinase activity of p38 in mouse uterus was gestation stage-dependent, and was markedly increased on day 19 of gestation and during labor. Immunohistochemical examination with anti-phospho p38 antibody revealed that activated p38 was predominantly localized in decidual stromal cells stained with anti-prolactin antibody. In human primary cultured decidual cells, a p38 inhibitor, SB202190, significantly inhibited both prostaglandin F(2alpha) production and COX-2 expression induced by stimulation with IL-1beta. These results suggest that the p38 signaling pathway is involved in decidual function at the late stage of gestation and may contribute to parturition.
Collapse
Affiliation(s)
- Y Takanami-Ohnishi
- Department of Biochemistry and Molecular Pharmacology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
Folliculo-stellate cells of the anterior pituitary are thought to modulate pituitary hormone secretion through a paracrine mechanism. Angiotensin II and pituitary adenylate cyclase-activating polypeptide (PACAP) have previously been shown to increase the intracellular Ca2+ concentration ([Ca2+]i) of these cells. In the present study, we examined the effects of various peptides such as bradykinin, angiotensin II, endothelin-1, PACAP, galanin and neurotensin by Ca2+-imaging of folliculo-stellate cells in primary culture. Bradykinin and angiotensin II increased [Ca2+]i in folliculo-stellate cells. Both responses were completely suppressed by thapsigargin and were significantly suppressed by the phospholipase C inhibitor, U-73122. Ryanodine did not significantly modify the responses. A B2 antagonist and angiotensin II receptor antagonist inhibited the response induced by bradykinin and angiotensin II, respectively. Endothelin-1 and PACAP increased [Ca2+]i in fewer than 50% of folliculo-stellate cells but galanin and neurotensin did not influence [Ca2+]i in any of the folliculo-stellate cells tested. These results indicate that bradykinin and angiotensin II increase [Ca2+]i in folliculo-stellate cells by activating phospholipase C through B2 receptor and AT1 receptor, respectively, and that endothelin-1 and PACAP also increase [Ca2+]i in some folliculo-stellate cells.
Collapse
Affiliation(s)
- T Sudo
- Department of Physiology, Nippon Medical School, Tokyo, Japan
| | | | | |
Collapse
|
35
|
Sudo T, Ito H, Ozeki Y, Kimura Y. Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method. Br J Pharmacol 2001; 133:1396-404. [PMID: 11498527 PMCID: PMC1621157 DOI: 10.1038/sj.bjp.0704204] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2001] [Accepted: 06/06/2001] [Indexed: 11/09/2022] Open
Abstract
1. The effects of anti-platelet drugs on human whole blood aggregation were evaluated using a novel whole blood aggregometer by a screen filtration pressure (SFP) method. 2. The SFP whole blood aggregometer was found to successfully detect whole blood aggregation induced by ADP, collagen and TRAP by measuring the SFP of blood samples. The platelet aggregation threshold index (PATI), the concentration of agonist required with an inducing pressure rate of 50%, varied time-dependently after collection of blood. High values for ADP and collagen were noted immediately after blood collection, suggesting low aggregation activity of platelets, and gradually increase thereafter. 3. Cilostazol (phosphodiesterase 3 inhibitor), dipyridamole, aspirin and tirofiban all inhibited whole blood aggregation in vitro. Inhibitory effects of cilostazol and dipyridamole, but not tirofiban, were markedly enhanced 6 or 7 fold by long pre-incubation (60 min), compared with short pre-incubation (2 min). Such enhancement was only observed with ADP- and not collagen-induced whole blood aggregation. A similar phenomenon was also observed for aggregation with platelet rich plasma (PRP). Cilostazol inhibition of ADP-induced platelet aggregation was more potent with PRP than whole blood (PATI(200)=3.80+/-0.95 microM for whole blood; 2.04+/-0.61 microM for PRP). Inhibitory effects of dipyridamole were attenuated in PRP without erythrocytes. 4. These results demonstrate that the SFP aggregometer can sensitively detect anti-platelet aggregatory effects of various kinds of drugs. So that it is a useful tool for evaluation of anti-platelet drugs.
Collapse
Affiliation(s)
- T Sudo
- Thrombosis and Vascular Research Laboratory, Otsuka Pharmaceutical Co., Ltd., 463-10 Kagasuno, Kawauchi-cho, Tokushima 771-0192, Japan.
| | | | | | | |
Collapse
|
36
|
Kobayashi K, Motohara T, Honma A, Takahashi R, Aihara M, Sudo T, Yoshizaki F. Augmentation of the pharmacological action of corydalis tuber by saussurea root in isolated mouse ileum. YAKUGAKU ZASSHI 2001; 121:647-51. [PMID: 11523125 DOI: 10.1248/yakushi.121.647] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
To understand the meaning of blending crude drugs in Chinese medicinal prescriptions, the influence of Saussurea root on the pharmacological action of Corydalis tuber was examined. Saussurea root increased the depression of acetylcholine-induced contraction caused by the hot water extract solution of Corydalis tuber in mouse ileum at low dosage, which showed no direct influence on acetylcholine. Dehydrocostuslactone in Saussurea root was characterized as the component having increasing activity and the relationship between the concentration of acetylcholine and the variation in the contraction depressed by Corydalis tuber alone or a mixture of the Corydalis tuber and dehydrocostuslactone was investigated for clarification of the mode of action.
Collapse
Affiliation(s)
- K Kobayashi
- Tohoku Pharmaceutical University, 4-1 Komatsushima 4-chome, Aoba-ku, Sendai 981-8558, Japan
| | | | | | | | | | | | | |
Collapse
|
37
|
Sano H, Sudo T, Yokode M, Murayama T, Kataoka H, Takakura N, Nishikawa S, Nishikawa SI, Kita T. Functional blockade of platelet-derived growth factor receptor-beta but not of receptor-alpha prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation 2001; 103:2955-60. [PMID: 11413086 DOI: 10.1161/01.cir.103.24.2955] [Citation(s) in RCA: 126] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
BACKGROUND The vascular smooth muscle cell (VSMC) is the central cell component involved in the fibroproliferative response in atherogenesis. As the lesion advances, VSMCs migrate from the media into the subendothelial space, thereby forming fibrous plaque lesions. Platelet-derived growth factor (PDGF) has been known to be a potent chemoattractant and mitogen for SMCs, but the pathophysiological role of the 2 PDGF receptors, receptor-alpha (PDGFR-alpha) and receptor-beta (PDGFR-beta) in atherogenesis is poorly understood. To clarify this problem, we prepared antagonistic rat monoclonal antibodies, APA5 and APB5, against murine PDGFR-alpha and PDGFR-beta, respectively. METHODS AND RESULTS Apolipoprotein E-deficient mice were fed a high-fat diet containing 0.3% cholesterol from 6 weeks of age and subjected to injection with 1 mg/d IP of either antibody from 12 to 18 weeks every other day. In the mice injected with APB5, the aortic atherosclerotic lesion size and the number of intimal VSMCs were reduced by 67% and 80%, respectively, compared with the control mice injected with irrelevant rat IgG. In contrast, the mice that received APA5 showed only minimal reduction of lesion size, and a large number of VSMCs were observed in the intima. In the intima of advanced lesions, APB5 immunolabeled VSMCs, whereas APA5 could detect VSMCs mainly in the media. CONCLUSIONS These results indicate that PDGFR-beta plays a significant role in formation of fibrous atherosclerotic lesions and that regulation of the signal transduction through PDGFR-beta could affect atherogenesis in mice.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/administration & dosage
- Aorta/drug effects
- Aorta/pathology
- Apolipoproteins E/deficiency
- Arteriosclerosis/pathology
- Arteriosclerosis/prevention & control
- Bone Marrow Cells/cytology
- Bone Marrow Cells/drug effects
- Cell Count
- Cells, Cultured
- Colony-Forming Units Assay
- Diet, Atherogenic
- Disease Models, Animal
- Disease Progression
- Fibrosis/pathology
- Immunohistochemistry
- Injections, Intraperitoneal
- Mice
- Mice, Knockout
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/drug effects
- Muscle, Smooth, Vascular/metabolism
- Rats
- Rats, Wistar
- Receptor, Platelet-Derived Growth Factor alpha/antagonists & inhibitors
- Receptor, Platelet-Derived Growth Factor alpha/metabolism
- Receptor, Platelet-Derived Growth Factor beta/antagonists & inhibitors
- Receptor, Platelet-Derived Growth Factor beta/metabolism
- Signal Transduction/drug effects
- Sinus of Valsalva/drug effects
- Sinus of Valsalva/pathology
Collapse
Affiliation(s)
- H Sano
- Departments of Geriatric Medicine, Graduate School of Medicine, Kyoto University, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Nakamura H, Isaka Y, Tsujie M, Akagi Y, Sudo T, Ohno N, Imai E, Hori M. Electroporation-mediated PDGF receptor-IgG chimera gene transfer ameliorates experimental glomerulonephritis. Kidney Int 2001; 59:2134-45. [PMID: 11380815 DOI: 10.1046/j.1523-1755.2001.00728.x] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Mesangial cell proliferation and phenotypic alteration occur in an early phase of glomerular injury and precede increased extracellular matrix accumulation. A critical growth factor responsible for mesangial proliferation is platelet-derived growth factor (PDGF), which has proved to be a potent mitogen. METHODS We generated a chimeric cDNA encoding an extracellular domain of the beta-PDGF receptor fused with IgG-Fc, termed PDGFR/Fc, and examined the feasibility of gene therapy targeting PDGF using PDGFR/Fc. RESULTS Chimeric PDGFR/Fc molecule completely inhibited the tyrosine phosphorylation of beta-PDGF receptors and cellular proliferation induced by PDGF in vitro. We then introduced the PDGFR/Fc expression vector into the muscle of anti-Thy-1 model of glomerulonephritic rats by electroporation. The plasma concentration of chimeric PDGFR/Fc levels was 244.4 +/- 89.8 ng/mL four days after transfection. On day 5, PDGFR/Fc gene transfer significantly reduced the number of PCNA-positive cells and glomerular cell numbers by 59.6 and 23.2%, respectively. Northern blot analysis demonstrated that glomerular mRNA levels of alpha-smooth muscle action, transforming growth factor-beta 1, and type I collagen were also suppressed on days 5 and 7 by the PDGFR/Fc transfection. There was a significant reduction in the matrix score of the transfected nephritic rats (2.91 +/- 0.75 and 2.06 +/- 0.95; disease control group vs. treated group, P < 0.001). CONCLUSION These results suggest that gene therapy by the manipulation of PDGF action using electroporation-mediated PDGFR/Fc gene transfer to the skeletal muscle might be a useful treatment for mesangioproliferative glomerulonephritis.
Collapse
Affiliation(s)
- H Nakamura
- Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Ohno N, Izawa A, Hattori M, Kageyama R, Sudo T. dlk inhibits stem cell factor-induced colony formation of murine hematopoietic progenitors: Hes-1-independent effect. Stem Cells 2001; 19:71-9. [PMID: 11209092 DOI: 10.1634/stemcells.19-1-71] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Delta-like (dlk) is a family of transmembrane proteins containing epidermal growth factor-like repeat motifs homologous to the notch/delta/serrate family. Recent studies suggest that dlk is a negative regulator of adipocyte differentiation, a promoting factor of cobblestone area colony formation, and a molecule which influences stromal cell-pre-B cell interactions and augments cellularity of developing thymocytes. However, the role of dlk in regulating the growth and differentiation of hematopoietic progenitors remains unclear. In the present study, we examined the effect of dlk on the proliferation of murine hematopoietic progenitors by hematopoietic growth factors. Soluble dlk-IgG Fc chimeric protein completely inhibited the colony formation of lineage-marker negative (Lin-) bone marrow cells by GM-CSF, G-CSF, or macrophage-CSF (M-CSF) in the presence of stem cell factor (SCF). However, dlk failed to inhibit the colony formation of Lin- bone marrow cells by CSF, as described above, or M-CSF plus interleukin 3. Furthermore, dlk failed to inhibit the colony formation of Hes-1-null fetal liver cells by M-CSF in the presence of SCF. These findings suggest that dlk is an important regulator of hematopoietic progenitor proliferation. Depending on the presence of SCF, dlk may act as a growth inhibitor, although dlk signaling does not mediate Hes-1 transcription factor.
Collapse
Affiliation(s)
- N Ohno
- Pharmaceutical Research Laboratories, Toray Industries, Inc., Tebiro, Kamakura, Japan
| | | | | | | | | |
Collapse
|
40
|
Takama H, Tanaka H, Sudo T, Tamura T, Tanigawara Y. Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study. Cancer Chemother Pharmacol 2001; 47:404-10. [PMID: 11391855 DOI: 10.1007/s002800000257] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
PURPOSE KRN5500, a novel spicamycin derivative, shows the greatest activity against a human tumor xenograft model and the highest therapeutic index among spicamycin derivatives. KRN5500 is currently under clinical development in Japan and the United States. The objective of this study was to develop a population pharmacokinetic model that describes the KRN5500 plasma concentration versus time data. METHODS Data were collected from 18 patients entered in a phase 1 study. These patients received KRN5500 3-21 mg/m2 as a 2-h infusion. A total of 219 concentration measurements were available. The data were analyzed using the nonlinear mixed effect model (NONMEM) program. In addition, the basic and final population pharmacokinetic models were evaluated using bootstrapping resampling. RESULTS The basic model selected was a two-compartment model with a combination of additive and constant coefficient of variation error models. The basic model fitted well not only the original data, but also 100 bootstrap replicates generated from the original data set. With regard to the effect of covariates selected by generalized additive modeling analysis, gender (SEX) and performance status were found to be possible determinants of the volume of central compartment by NONMEM analysis. The final regression model for V1 was V1 = theta V1 (1--SEX x theta SEX), where V1 is the typical population value of the volume of central compartment, and SEX = 0 if the patient is male, otherwise SEX = 1. The final model was fitted to the 200 bootstrapped samples. The mean parameter estimates were within 15% of those obtained with the original data set. CONCLUSIONS The KRN5500 plasma concentration versus time data obtained from the phase 1 study were well described by the population pharmacokinetic model. Further evaluation by bootstrapping showed that the population pharmacokinetic model was stable.
Collapse
Affiliation(s)
- H Takama
- Product Development Department, Pharmaceutical Division, Kirin Brewery Company Ltd., 26-1 Jingumae 6-chome, Shibuya-ku, Tokyo, 150-8011, Japan.
| | | | | | | | | |
Collapse
|
41
|
Affiliation(s)
- T Sudo
- Biodesign Group, Institute of Physical and Chemical Research, Saitama, Japan
| | | |
Collapse
|
42
|
Ozeki Y, Sudo T, Toga K, Nagamura Y, Ito H, Ogawa T, Kimura Y. Characterization of whole blood aggregation with a new type of aggregometer by a screen filtration pressure method. Thromb Res 2001; 101:65-72. [PMID: 11342207 DOI: 10.1016/s0049-3848(00)00377-7] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
A new type of platelet aggregometer of whole blood, based on the screen filtration pressure method, has been developed and characterized. It measures resistance of flow of whole blood samples through a screen of microsieve with 30-microm(2) openings and provides pressure rate as an index of platelet aggregation. On optical microscopic observation, platelet aggregates, but not fibrin fibers, were found to be trapped on microsieves, and the pressure rate and protein amounts on microsieves are correlated. The aggregometer showed good reproducibility for investigations performed on different days. The time course of pressure rates indicated a bell curve change, where the pressure rate was very low immediately after blood collection and gradually increased up to 60 min thereafter. Use of the aggregometer was able to confirm that orally administered aspirin inhibits ADP- and collagen-induced whole blood aggregation as well as platelet aggregation. The results suggest that this platelet aggregometer might be useful in research and clinical diagnosis of thrombotic diseases.
Collapse
Affiliation(s)
- Y Ozeki
- 1st Institute of New Drug Research, Otsuka Pharmaceutical Co., Ltd., 463-10 Kagasuno, Kawauchi-cho, 771-0192, Tokushima, Japan.
| | | | | | | | | | | | | |
Collapse
|
43
|
Abstract
p38 has been implicated to play a critical role in regulating apoptosis in PC12 and cerebellar granule cells, and is inactivated in cultured fetal neurons in response to insulin. Though p38 is activated in microglia after ischemia, the physiological functions of p38 in the brain are not well understood. As a first step to elucidate the physiological functions of p38 in the central nervous system, we raised a polyclonal antibody against p38 and performed immunohistochemical examination to demonstrate the localization of p38 in mouse brain. Strong p38 immunoreactivity was apparent in fiber bundles including the olfactory tract, anterior commissure, corpus callosum, cingulum, internal capsule, stria terminalis, fimbria and alveus hippocampi, fornix, stria medullaris, optic chiasm and optic tract. Although similar regions were stained with both anti-p38 and anti-neurofilament antibodies, intense p38 immunoreactivity was often observed in myelin sheath-like structures but not in axons. This is the first demonstration of the localization of p38 in the central nervous system and provides an anatomical basis for understanding physiological roles of p38.
Collapse
Affiliation(s)
- M Maruyama
- Antibiotics Laboratory, RIKEN, 2-1 Hirosawa Wako, Saitama 351-0198, Japan
| | | | | | | | | | | |
Collapse
|
44
|
Matsumoto M, Sudo T, Maruyama M, Osada H, Tsujimoto M. Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor. FEBS Lett 2000; 486:23-8. [PMID: 11108836 DOI: 10.1016/s0014-5793(00)02231-6] [Citation(s) in RCA: 70] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Tumor necrosis factor (TNF) induces osteoclast differentiation from bone marrow cells in the presence of macrophage colony-stimulating factor. Treatment of bone marrow cells with SB203580 but not PD98059 inhibited TNF-induced osteoclast differentiation. In RAW264 cells which differentiate into osteoclast-like multinucleated cells by TNF treatment alone, activation of p38 mitogen-activated protein (MAP) kinase induced by murine TNF was comparable to and independent of the receptor activator of necrosis factor-kappaB ligand. Moreover, the number of multinucleated osteoclasts induced by TNF in bone marrow cell cultures derived from p38 MAP kinase gene deficient mice was significantly less than that from control mice. These results indicate that the p38 MAP kinase pathway plays a crucial role in TNF-mediated osteoclast differentiation.
Collapse
Affiliation(s)
- M Matsumoto
- Laboratory of Cellular Biochemistry, RIKEN (The Institute of Physical and Chemical Research) Saitama, Japan
| | | | | | | | | |
Collapse
|
45
|
Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 2000; 275:31155-61. [PMID: 10859303 DOI: 10.1074/jbc.m001229200] [Citation(s) in RCA: 445] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
The receptor activator of NF-kappaB ligand (RANKL) induces osteoclast differentiation from bone marrow cells in the presence of macrophage colony-stimulating factor. We found that treatment of bone marrow cells with SB203580 inhibited osteoclast differentiation via inhibition of the RANKL-mediated signaling pathway. To elucidate the role of p38 mitogen-activated protein (MAP) kinase pathway in osteoclastogenesis, we employed RAW264 cells which could differentiate into osteoclast-like cells following treatment with RANKL. In a dose-dependent manner, SB203580 but not PD98059, inhibited RANKL-induced differentiation. Among three MAP kinase families tested, this inhibition profile coincided only with the activation of p38 MAP kinase. Expression in RAW264 cells of the dominant negative form of either p38alpha MAP kinase or MAP kinase kinase (MKK) 6 significantly inhibited RANKL-induced differentiation of the cells. These results indicate that activation of the p38 MAP kinase pathway plays an important role in RANKL-induced osteoclast differentiation of precursor bone marrow cells.
Collapse
Affiliation(s)
- M Matsumoto
- Laboratories of Cellular Biochemistry and Antibiotics, RIKEN (The Institute of Physical and Chemical Research), 2-1 Hirosawa, Wako, Saitama, 351-0198 Japan
| | | | | | | | | |
Collapse
|
46
|
Tani T, Uehara K, Sudo T, Marukawa K, Yasuda Y, Kimura Y. Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. Atherosclerosis 2000; 152:299-305. [PMID: 10998457 DOI: 10.1016/s0021-9150(99)00480-3] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Cilostazol, a selective type III phosphodiesterase inhibitor, has antiplatelet and vasodilating effects. In this study, the effects of cilostazol on lipid metabolism and lipoprotein lipase (LPL) activity were studied in rats. Cilostazol was administered orally at doses of 30 or 100 mg/kg twice a day for 1-2 weeks to rats. Cilostazol decreased the serum triglyceride level in normolipidemic rats. The serum triglyceride level was reduced and HDL cholesterol level was increased by cilostazol in streptozotocin (STZ)-induced diabetic rats. The disappearance of exogenous triglyceride was accelerated by cilostazol in normolipidemic rats. Cilostazol increased post-heparin plasma LPL activity but had no effect on hepatic triglyceride lipase activity in STZ-induced diabetic rats. Cilostazol also increased LPL activity in the heart in STZ-induced diabetic rats. These findings suggest that an increase in LPL activity is responsible for the serum triglyceride lowering and HDL cholesterol elevating effects of cilostazol in rats.
Collapse
Affiliation(s)
- T Tani
- Tokushima Research Institute, Otsuka Pharmaceutical Co. Ltd., 463-10 Kagasuno Kawauchi-cho, 771-0192, Tokushima, Japan
| | | | | | | | | | | |
Collapse
|
47
|
Kishi M, Itagaki Y, Takakura R, Imamura M, Sudo T, Yoshinari M, Tanimoto M, Yasue H, Kashima N. Nuclear transfer in cattle using colostrum-derived mammary gland epithelial cells and ear-derived fibroblast cells. Theriogenology 2000; 54:675-84. [PMID: 11101030 DOI: 10.1016/s0093-691x(00)00382-4] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
To assess the developmental potential of nuclear transfer embryos in cattle using mammary gland epithelial (MGE) cells derived from the colostrum, we compared the effectiveness of cloning using those cells and fibroblast cells derived from the ear. The fusion rate of the enucleated oocytes with fibroblast cells (75 +/- 4%) was significantly higher than that with MGE cells (56 +/- 7%, P<0.05). There were no significant differences in the cleavage rate (85 +/- 3% vs. 91+/- 2%) or in the developmental rate to the blastocyst stage (35 +/- 6% vs. 35 +/- 5%) using MGE cells vs. fibroblast cells as donor nuclei (P>0.05). After transfer of blastocysts derived from nuclear transfer embryos produced using MGE cells and fibroblast cells, 13% (4/31) and 16% (6/37) of recipient heifers were pregnant on Day 42 as assessed by ultrasonography, respectively. Two of the 4 and 4 of the 6 recipients of embryos with MGE cell- and fibroblast cell-derived nuclei, respectively, aborted within 150 days of pregnancy. Four live female calves were obtained from MGE cells or fibroblast cells. However, one died from internal hemorrhage of the arteria umbilicalis. The other three calves were normal and healthy. There were no differences in the pregnancy rate or calving rate when using MGE cells vs. fibroblast cells. Microsatellite DNA analyses confirmed that the cloned calves were genetically identical to the donor cows and different from the recipient heifers. We conclude that colostrum-derived MGE cells have the developmental potential to term by nuclear transfer, and the efficiency of development of those cloned embryos was the same as that of embryos obtained using fibroblast cells as donor nuclei, although there was a significant difference in the fusion rate. This method using MGE cells derived from colostrum, which is obtained easily and safely from live adult cows, is more advantageous for cloning with somatic cells.
Collapse
Affiliation(s)
- M Kishi
- Embryo Transplantation Laboratory, Snow Brand Milk Products Co Ltd Tomakomai, Hokkaido, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Ito T, Udaka N, Yazawa T, Okudela K, Hayashi H, Sudo T, Guillemot F, Kageyama R, Kitamura H. Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development 2000; 127:3913-21. [PMID: 10952889 DOI: 10.1242/dev.127.18.3913] [Citation(s) in RCA: 263] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
To clarify the mechanisms that regulate neuroendocrine differentiation of fetal lung epithelia, we have studied the expression of the mammalian homologs of achaete-scute complex (Mash1) (Ascl1 - Mouse Genome Informatics); hairy and enhancer of split1 (Hes1); and the expression of Notch/Notch-ligand system in the fetal and adult mouse lungs, and in the lungs of Mash1- or Hes1-deficient mice. Immunohistochemical studies revealed that Mash1-positive cells seemed to belong to pulmonary neuroendocrine cells (PNEC) and their precursors. In mice deficient for Mash1, no PNEC were detected. Hes1-positive cells belong to non-neuroendocrine cells. In the mice deficient in Hes1, in which Mash1 mRNA was upregulated, PNEC appeared precociously, and the number of PNEC was markedly increased. NeuroD (Neurod1 - Mouse Genome Informatics) expression in the lung was detected in the adult, and was enhanced in the fetal lungs of Hes1-null mice. Expression of Notch1, Notch2, Notch3 and Notch4 mRNAs in the mouse lung increased with age, and Notch1 mRNA was expressed in a Hes1-dependent manner. Notch1, Notch2 and Notch3 were immunohistochemically detected in non-neuroendocrine cells. Moreover, analyses of the lungs from the gene-targeted mice suggested that expression of Delta-like 1 (Dll1 - Mouse Genome Informatics) mRNA depends on Mash1. Thus, the neuroendocrine differentiation depends on basic helix-loop-helix factors, and Notch/Notch-ligand pathways may be involved in determining the cell differentiation fate in fetal airway epithelium.
Collapse
Affiliation(s)
- T Ito
- Department of Pathology, Yokohama City University School of Medicine, Yokohama, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Abstract
Inhalation of furosemide, a loop diuretic, has shown favorable effects on experimentally induced cough, bronchoconstriction, and dyspnea. The effect of inhaled furosemide on tracheobronchial receptors was studied in anesthetized, spontaneously breathing rats. Single unit or pauci unit activity was recorded from the right vagus nerve. Tracheobronchial receptors were classified into slowly and rapidly adapting receptors (SARs and RARs, respectively), based on their adaptation index (AI), which was derived from the decrease in spike frequency (sf) over 2 s, expressed as a percentage of the peak firing rate. There were 43 SARs (AI </= 25%) and eight RARs (AI >/= 50%). Inhalation of furosemide (n = 29) increased the slope of airway pressure (Paw) versus sf of SARs from 8.6 to 14.8 Hz/cm H(2)O with an increase in sf at Paw = 0 cm H(2)O from 18.0 to 49.5 Hz, resulting in an upward shift of the line. Neither inhalation of vehicle (n = 9) nor intravenous injection of furosemide (n = 5) changed this relationship. In addition, inhalation of furosemide attenuated the activity of RARs. These findings indicate that SARs are sensitized and RARs desensitized by inhalation of furosemide. We discuss possible mechanisms for this, and its relevance to clinical problems of dyspnea, bronchoconstriction, and cough.
Collapse
Affiliation(s)
- T Sudo
- Departments of Anesthesiology and Physiology, School of Medicine, Chiba University, Chiba City, Japan
| | | | | |
Collapse
|
50
|
Iino S, Sudo T, Niwa T, Fukasawa T, Hidaka H, Niki I. Annexin XI may be involved in Ca2+ - or GTP-gammaS-induced insulin secretion in the pancreatic beta-cell. FEBS Lett 2000; 479:46-50. [PMID: 10940386 DOI: 10.1016/s0014-5793(00)01877-9] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The aim of this study was to investigate possible involvement of annexin XI in the insulin secretory machinery. In fluorescence immunocytochemistry, annexin XI was found in the cytoplasm of pancreatic endocrine cells and a pancreatic beta-cell line, MIN6, in a granular pattern. MIN6 cells also possessed weak and diffused annexin XI immunoreactivity in the cytoplasm. Immunoelectron microscopy revealed annexin XI in the insulin granules. Insulin secretion from streptolysin-O-permeabilized MIN6 cells was inhibited by anti-annexin XI antibody, when the release was stimulated by either Ca2+ or GTP-gammaS, but not by a protein kinase C-activating phorbol ester. Inhibition of insulin release by anti-annexin XI antibody was reproduced in permeabilized rat islets. These findings suggest that annexin XI may be involved in the regulation of insulin secretion from the pancreatic beta-cells.
Collapse
Affiliation(s)
- S Iino
- First Department of Anatomy, Nagoya University School of Medicine, Japan
| | | | | | | | | | | |
Collapse
|